Novo Nordisk launches a new cash-pay option for a leading diabetes drug, changing affordability dynamics for uninsured patients across the U.S.

(CNN) - Patients in the United States can now get the popular diabetes and weight loss drug Ozempic for half the price. Novo Nordisk, the maker of the GLP-1 drug Ozempic, announced Monday that U.S. patients can now get a month’s supply for just under $500. It typically carries a list price of around $1,000 a month.

A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark ... Novo Nordisk has filed 14 lawsuits in the United States against companies selling duplicates of its obesity drugs, in an effort to “safeguard ...

In the UK, patients can buy a four-week supply of Ozempic for between £119 and £190 from online pharmacies. Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump.

GLP-1 weight-loss drugs are creating “mortality slippage” in life insurance which is a costly problem that's forcing insurers to rethink how they underwrite.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and Wego